The aim of this review is to summarize the best available evidence on the contribution of 18 subcutaneous and/or intra-abdominal adipose tissues to the incidence of impaired glucose 19 tolerance and/or type 2 diabetes mellitus, in adults as well as to determine which type of 20 abdominal fat is a better predictor of these metabolic disorders. 21
INTRODUCTION 51
Abdominal or central obesity comprises excess of visceral and subcutaneous fat depots 52 around the abdomen. It is one of the major features associated with many, components of the 53 metabolic syndrome, including impaired glucose tolerance (IGT) and type 2 diabetes mellitus 54 (T2DM) (1-4). 55
Recently, two meta-analyses have shown that anthropometric measurements of 56 abdominal adiposity, assessed by waist circumference -WC and waist circumference/height ratio 57 -WHR) or of general obesity, assessed by body mass index-BMI, are strong predictors of T2DM 58 incidence (5, 6). These findings were confirmed by a long-term longitudinal study in which 59 anthropometric measurements were used as a surrogate for body fat and abdominal fat (7). 60
Nevertheless, the aforementioned studies, for technical reasons, could not provide further 61 information on the weighted role of the subcutaneous and the visceral components of the 62 abdominal fat on the risk for development of . 63
Several studies that applied quantitative imaging methods to assess both subcutaneous 64 and intra-abdominal adipose tissue showed that visceral fat is more strongly correlated to 65 metabolic risks than increased abdominal subcutaneous fat (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . And some authors have 66 found that the latter is not linearly associated with the increase of metabolic abnormalities as it is 67 observed in relation to increased intra-abdominal fat (17). They argue that increased abdominal 68 subcutaneous fat might actually be metabolically protective in obese individual (25) . 69
However, due to the cross-sectional and observational designs of the aforementioned 70 studies, it is not possible to assess the relative risk of each component of the abdominal adipose 71 tissue to the development of IGT and/or T2DM. 72 Addressing this issue, a few longitudinal studies showed that increased intra-abdominal 73 adipose tissue is strongly associated with the incidence of IGT and/or T2DM (11, [26] [27] [28] [29] [30] . 74
In addition, a historical cohort study that applied quantitative imaging methods to assess 75 (dual-energy X-ray absorptiometry-DXA) confirmed the previous findings that higher amount of 76 abdominal fat increased the risk to develop T2DM in a large cohort of Canadians women (11) . 77 We, therefore, proposed to summarize the evidence showing the contribution of 78 subcutaneous and/or intra-abdominal adipose tissues to the incidence of impaired glucose 79 tolerance and/or type 2 diabetes mellitus, in adults, through a systematic review of prospective 80 studies. Furthermore, we aimed to determine which type of abdominal fat (i.e., subcutaneous 81 and/or intra-abdominal) is a better predictor of the aforementioned metabolic disorders. 82
METHODS 83

Types of participants 84
Studies were included if participants of interest were adults (>18 years), regardless 85 gender or ethnicity, who did not have diabetes mellitus at baseline, and were followed for at least 86 two years until the occurrence of dysglycemia (impaired glucose tolerance and/or type 2 diabetes 87 mellitus). Furthermore, the patients should have had meas urements of visceral and/or 88 subcutaneous adipose tissue (VAT and abdominal SAT, respectively) content values by validated 89 abdominal imaging methodology (i.e., computerized tomography-CT, magnetic resonance 90 imaging-MRI), expressed as continuous or categorical values or baseline means for cases 91 (subjects who developed dysglycemia) and controls (subjects who has not developed 92 dysglycemia). 93
Types of studies 94
This review included inception cohort studies as they have a prospective design feature 95 over a period of time. 96
In order to answer the question regarding which type of abdominal fat would pose more 97 risk to the development of IGT or T2DM, the studies should contain reports of differential odds 98 ratio (OR) or hazard ratio (HR) for each fat type for the development of the outcome. 99
Types of outcome measures 100
The primary outcome of this review is the development of IGT and/or T2DM. The 101 exposure was subcutaneous and/or intra-abdominal adipose tissue measurements at baseline. 102 Impaired fasting glucose (IFG) was defined as fasting glucose between 100 mg/dl and 103 199 mg/dl. Impaired glucose tolerance was defined by 2-h plasma glucose level between 140 104 mg/dl and 199 mg/dl after a standard oral glucose tolerance test (31). Diabetes mellitus type 2 105 was defined as fasting plasma glucose ≥ 126 mg/dl or 2-h plasma glucose level ≥200 mg/dl after 106 a glucose challenge (31), as well as patient's reports or medical records informing treatment with 107 insulin or oral antidiabetic agents during follow up. 108 In addition, reference lists of the identified relevant studies were scrutinized for 115 additional citations and, specialists in the field and authors of the included trials were contacted 116 for any possible unpublished data. 117
Search strategy for identification of studies
Data collection and extraction 118
Two reviewers (AVBC and VSN) independently screened the studies identified by the 119 literature search and extracted data. Subsequently, disagreements between the examiners were 120 discussed between authors (AVBC and RED) to reach consensus. 121
Quality assessment 122
Clinical and imaging information that would influence the applicability and interpretation 123 of findings and would be necessary to allow assessment of the homogeneity of studies included 124 in this review, such as sex, age, ethnicity, duration of follow up, year of study and components of 125 abdominal fat, were extracted. 126
The risk of bias was assessed by examining the sample selected, recruitment method, 127 completeness of follow up and blinding according to the guidelines for assessing quality in 128 prognostic studies proposed by Hayden (32) and the MOOSE (33) statement, and adapted by us. 129
Studies were assigned as being low risk if the sample came from a population base, the follow up 130 period was prospective and the withdrawals and drop-outs was less than 20% of the sample for 131 each group. Studies could receive a low, high or uncertain risk of bias classification. 132
Data management and statistical analysis 133
We have presented the information in a way in which variations in similar outcomes can 134 be examined, taking into account length of follow up, age at ascertainment and other clinically 135 important differences such as sex, age, family history, diagnosis of IGT at baseline when the 136 information was available. Using the available data reported, we ca lculated 95% confidential 137 intervals (CI) around the odds ratio (STATA 10.1) and used Review Manager 5 software to 138 combine results in a forest plot using a random-effect model. Pooled odds ratio analysis was 139 performed with STATA, v. 10.1. 140 Where some data was missing, attempt were made to contact authors of the primary 141 studies. If there was no response or there was response but could not provide data, such 142 outcomes were excluded from analysis. Studies with missing outcomes were described in 143 characteristics of included studies table. 144
Investigation of heterogeneity 145
Heterogeneity of the studies was explored within the Chi 2 test and the I 2 statistics (32) 146 that provide the relative amount of variance of the summary effect due to the between-study 147 heterogeneity. We classified heterogeneity using the following I 2 values: 0 to 40%: might not be 148 important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent 149 substantial heterogeneity; and 75% to 100%: considerable heterogeneity. 150
If there was a substantial heterogeneity, the possible sources of heterogeneity were 151 explored by removing studies with low methodological quality. 152
RESULTS
153
Study selection process and results from the literature search are depicted in Figure 1 . In 154 summary, we identified 6783 studies from the following database: Medline (n=3874), EMBASE 155 (n=2715), Cochrane (Central) (n=196), Lilacs (n=198). After exclusion of duplicate records and 156 studies that have not met our inclusion criteria, 35 studies, potentially eligible for inclusion, were 157 requested and 19 full-text articles were selected. Following assessment of the full-text articles, 158 five publications met all the methodological requirements and were included in this review. 159
Detailed characteristics of the excluded and included studies are described in Tables 1 and 2 . All 160 studies received a low risk of bias. 161
The samples size varied from 128 (27) to 2356 (28) participants. The studies involved 162 both young and elderly Japanese-American (11, 26, 27, 29, 30) , African-American (29), 163 Hispanic-American (29), white and black Americans (28) from both sexes. 164
The follow up time ranged from 5 to 11 years. Approximately 70-90% of the participants 165 completed the study. At baseline, all participants had measurements of abdominal fat content by 166
CT. 167
The outcomes were assessed by OGTT in 3 out of 5 studies (26, 27, 30) and/or by 168 medical records, self-reports or fasting glycemia ≥126 mg/dl (28, 29) . 169
Among the participants, a total of 414/4556 subjects (9.1%) developed T2DM and 57/128 170 subjects (44.5%) developed IGT (Table 2) . 171
The studies used odds ratio (OR) and the accompanying 95% confidence intervals to 172 assess the incidence of T2DM or IGT in relation to baseline measurements of VAT and 173 abdominal SAT. In one study (28), it was not possible to retrieve unavailable information about 174 the the odds ratio of SAT to predict incident T2DM. The results are summarized in Table 3 . 175
Assessment of confounding factors such as age and sex was performed in all studies. The 176 inclusion of other confounding variables to the calculation of OR for the incidence of T2DM and 177
IGT such as BMI, total adiposity, insulin sensitivity, family history, IGT at baseline and others 178 varied in composite among all studies. 179
The pooled OR for dysglycemias, in relation to baseline VAT e SAT measurements, in 180 minimally adjusted models (age, sex and ethnicity), were 1.59 (CI = 1.39-1.78) e 1.48 (CI = 181 1.26-1.70), with evidence of moderate heterogeneity, I 2 = 75% (Pheterogeneity = 0.03) e 54% 182 (Pheterogeneity = 0.09); whilst in maximally adjusted models (age, sex, race, IGT, insulin 183 sensitivity, insulin secretion, fasting blood insulin, C-peptide, lipids, adipokines etc), the pooled 184 OR were 1.37 (1.15-1.58) and 0.89 (0.71-1.07), with low (34%, Pheterogeneity = 0.20) and 185 moderate heterogeneity (72%, Pheterogeneity = 0.01) 186
Insulin sensitivity and secretion were still stronger predictors of diabetes development 187 than VAT measurements when they were modeled together (29). In one of the studies, the 188 authors also showed that BMI was a strong predictor of incident T2DM in both white and black 189 subjects, but this association decreased when other confounding variables were taken into 190 account (adipokines, fasting glucose, lipids, and hypertension) and held significantly only for 191 white subjects (24). Subjects that developed T2DM presented higher indexes of general obesity 192 (BMI), VAT or abdominal SAT (Figures 2 and 3 ) and other characteristic of regional obesity 193 (WC, thigh fat) at baseline than those who have not (data not shown). 194
In all studies, participants that developed T2DM presented baseline values of BMI, VAT 195 and abdominal SAT or total abdominal fat significantly higher than those who did not developed 196 T2DM (Figures 2 and 3) . Participants that developed IGT also presented higher VAT and 197 abdominal SAT compared to those who presented normal glucose tolerance (Figures 2 and 3) . 198 DISCUSSION 199 Recently, two meta-analyses have shown that anthropometric measurements of 200 abdominal fat (i.e. WC and WHR) or general obesity (i.e. BMI) are strong predictors of the 201 development of T2DM (5, 6), and these findings were confirmed by a long-term longitudinal 202 study (7). The assessment of abdominal fat by direct methods also showed that increased 203 abdominal fat is a strong predictor of both IGT and T2DM (14, 27, 30) . In the present review, we 204 also found that the group of patients who developed dysglycemia presented, at baseline 205 assessment, higher BMI, VAT and SAT values than those who have not developed those 206 metabolic disorders. 207
In addition, the present review also suggested that, adjusting for age, sex and ethnicity, 208 both VAT and abdominal SAT measurements are strong predictors of incident dysglycemia. 209
However, when other confounders are added to risk calculations only VAT measurements poses 210 higher risk to the incidence of IGT or T2DM than abdominal SAT, in a wide range of age and 211 ethnic backgrounds (Japanese-, Hispanic-, African-Americans). These results are in consonance, 212 with a large set of studies that indicates that expanded visceral fat plays a major role in the 213 development of insulin resistance, and ultimately of impaired glucose tolerance and type 2 214 diabetes mellitus (4, (34) (35) (36) . 215 However, the issue about which component of abdominal fat pose a major impact on the 216 relationship on the development of insulin resistance and dysglycemia is still a matter of interest 217 and debate. Some showed that both visceral and abdominal subcutaneous fat were equally 218 associated to the presence of insulin resistance (37, 38), whilst others showed a major role of 219 abdominal SAT (39). In this review, it was noted that abdominal SAT, similarly to VAT is a risk 220 factor to the development of both IGT and T2DM (OR: 1.48 x 1.59, respectively), in minimally 221 adjusted models for confounding factors (age, sex and ethnicity). However, after adjusting to 222 other risk factors (e.g. insulin sensitivity or secretion, adiponectin levels etc) SAT does increase 223 the risk to the development of dysglycemia (OR: 0.89). 224
Although the results of this meta-analysis may highlight VAT as a stronger predictor of 225 IGT and T2DM than other measurements of overall and regional adiposity, they do not allow 226 drawing conclusions regarding the direct causal role of VAT on the development of those 227 metabolic disorders. Several attempts have been made to show a direct role of VAT in metabolic 228 profile. In animals models, for instance, reduction of VAT, by means of the excision of the 229 omentum, showed improvement of insulin sensitivity and glucose tolerance (40, 41). However, 230 in morbidly obese and diabetic patients, omentectomy has not added improvement to insulin 231 sensitivity in relation to bariatric surgery itself (42, fat, particularly VAT, and metabolic disorders. It has been shown that increased VAT is 238 associated with dysfunctional adipocytes which present higher rates of lipolysis, partly due to a 239 higher sensitivity to adrenergic drive, which could lead to an overflow of free fatty acids (FFA) 240 or adipokines to the liver, as well as to the muscle, compromising liver and muscle insulin 241 sensitivity, insulin clearance and ultimately leading to the development of T2DM. Moreover, 242 VAT is prone to inflammation which also leads to insulin resistance (45, 46) . Another 243 observation that has recently gained attention is that VAT is associated with ectopic fat 244 deposition (liver, muscle, pancreas etc) which is also highly correlated with the development of 245 IGT and T2DM (44, 47) . In some studies, it was shown that fatty liver had a stronger association 246 with T2DM than VAT per se (20, 48) . These studies suggest that VAT may be a bystander in the 247 association of regional obesity and metabolic disorders or a marker of underlying causes of 248 disorders of insulin secretion or sensitivity such as ectopic deposition of fat in liver, muscle and 249
pancreas. 250
It is interesting to note that studies have shown that the deeper part of abdominal SAT 251 present morphological and functional characteristic similar to VAT (49), which potentially could 252 confer this site of abdominal SAT similar influence on the risk of developing insulin 253 resistance/dysglycemia as VAT. On the other hand, other regional SAT, such as thigh, has been 254 reported as protective against metabolic disorders (50, 51) . 255
Several potential limitations are present in this study. Our analyses were based on few 256 studies which could lead to publication bias. In a considerate number of studies the diagnosis of 257 T2DM was based in self-report or fasting glucose measurements which may result in misleading 258 incidence of T2DM. Information about changes of VAT and abdominal SAT overtime to predict 259 the incident of ITG and T2DM are also important to OR calculation but were not assessed in the 260 studies. Moreover, only one study addressed the prediction of IGT (27) . 261
In contrast, the strengths of this study are the involvement of a wide range of age and 262 ethnic backgrounds and the feasibility to tease out the predictive values of the components of the 263 abdominal fat (VAT and abdominal SAT) to the development of IGT and T2DM, using direct 264 measurements of abdominal fat. 265
In conclusion, the present results provide some evidence that increased abdominal fat 266 may be a significant risk factor for the development T2DM and possibly to IGT across different 267 ethnic backgrounds and age. Our data also suggest that VAT imposes more risk to the 268 development of dysglycemia than abdominal SAT. However, more studies are necessary to 269 confirm these results and to address the issue of changes in VAT and abdominal SAT and their 270 predictive value regarding IGT and type 2 diabetes developments. Studies assessing the 271 predictive role of ectopic fat deposition (liver, muscle and pancreas) on this association are also 272 warranted. 273
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JACDS-Japanese American Community Diabetes Study; dysglycemia -impaired glucose tolerance (ITG) and diabetes mellitus (DM ); OGTT -oral glucose tolerance test, CTcomputerized tomography; VAT -visceral adipose tissue; SAT -subcutaneous adipose tissue; IIR -Index of insulin resistance; IR-insulin resistance, FPG-fasting plasma glucose; TG -triglyceride; sBP-systolic blood pressure; STF -subcutaneous total fat 
